| Dr James E Jolley Ii, MD | |
|
281 North Lyerly Street, Suite 300, Chattanooga, TN 37404 | |
| (423) 693-2175 | |
| (888) 959-1015 |
| Full Name | Dr James E Jolley Ii |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 26 Years |
| Location | 281 North Lyerly Street, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457392433 | NPI | - | NPPES |
| MD31776 | Other | TN | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | MD31776 (Tennessee) | Secondary |
| 207XS0117X | Orthopaedic Surgery - Orthopaedic Surgery Of The Spine | MD31776 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Healthcare System, Inc | Chattanooga, TN | Hospital |
| Parkridge Medical Center | Chattanooga, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southeastern Spine Pllc | 8628226131 | 4 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Hesperos Inc., pioneers of the "human-on-a-chip" in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known cardiotoxic small molecules over time, to accurately describe the drug behavior and toxic effects in vivo.
There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
According to a latest study many medical devices recalled in recent years by the Food and Drug Administration (FDA) because they posed a high risk to patients were not rigorously studied before being approved for patient use. The study, appearing on the web site of The Archives of Internal Medicine, said that most medical devices that were the subject of high-risk recalls from 2005 to 2009 had been cleared through a regulatory pathway with little testing. This included external heart defibrillators, hospital infusion pumps and mechanical ventilators.
› Verified 9 days ago
| Entity Name | Southeastern Spine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518215219 PECOS PAC ID: 8628226131 Enrollment ID: O20120906000845 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Hesperos Inc., pioneers of the "human-on-a-chip" in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known cardiotoxic small molecules over time, to accurately describe the drug behavior and toxic effects in vivo.
There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
According to a latest study many medical devices recalled in recent years by the Food and Drug Administration (FDA) because they posed a high risk to patients were not rigorously studied before being approved for patient use. The study, appearing on the web site of The Archives of Internal Medicine, said that most medical devices that were the subject of high-risk recalls from 2005 to 2009 had been cleared through a regulatory pathway with little testing. This included external heart defibrillators, hospital infusion pumps and mechanical ventilators.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James E Jolley Ii, MD 281 North Lyerly Street, Suite 300, Chattanooga, TN 37404 Ph: (423) 693-2175 | Dr James E Jolley Ii, MD 281 North Lyerly Street, Suite 300, Chattanooga, TN 37404 Ph: (423) 693-2175 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the "Advances in Biopharmaceuticals" Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.
Hesperos Inc., pioneers of the "human-on-a-chip" in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known cardiotoxic small molecules over time, to accurately describe the drug behavior and toxic effects in vivo.
There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
According to a latest study many medical devices recalled in recent years by the Food and Drug Administration (FDA) because they posed a high risk to patients were not rigorously studied before being approved for patient use. The study, appearing on the web site of The Archives of Internal Medicine, said that most medical devices that were the subject of high-risk recalls from 2005 to 2009 had been cleared through a regulatory pathway with little testing. This included external heart defibrillators, hospital infusion pumps and mechanical ventilators.
› Verified 9 days ago
Eric Peter Clarke, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2707 Citico Avenue, Chattanooga, TN 37406 Phone: 423-624-8588 Fax: 423-622-3069 | |
Julie Elizabeth Adams, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 979 E 3rd St Ste C225, Chattanooga, TN 37403 Phone: 423-778-5995 Fax: 423-778-5994 | |
Dr. J Paul Martz, D.O. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2415 Mccallie Ave, Chattanooga, TN 37404 Phone: 423-624-2696 Fax: 423-697-2055 | |
Fred Barry Hodges Iii, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 979 E 3rd St, Ste C-220, Chattanooga, TN 37403 Phone: 423-267-4585 Fax: 423-265-4098 | |
Dr. Jeremy Reginald Bruce, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-877-9297 | |
Dr. James Patterson Stone, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 2415 Mccallie Ave, Chattanooga, TN 37404 Phone: 423-624-2696 Fax: 423-697-2055 | |
Dr. Adam M Caputo, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1736 Gunbarrel Rd, Chattanooga, TN 37421 Phone: 423-756-6623 |